ResearchSafe

Senolytics may clear 70% of aging cells in preclinical study

Posted by student748 in Longevity & Anti-Aging - 12 points, 7 comments.

https://medicalxpress.com/news/2026-02-preclinical-senolytics-zombie-cells.html

There's a new preclinical study making the rounds that senolytics can clear up to 70% of those zombie senescent cells that accumulate with age. The research looked at aged blood vessel cells and how they drive metabolic diseases. I've been tracking the senolytic space for a while now, rapamycin, NR, the whole longevity stack, and this feels like one of those foundational pieces that could shift how people think about aging beyond just "take this supplement for energy." What I'm curious about is whether the effect holds up in humans; a lot of the early data is in mice or cell cultures, and I've seen plenty of compounds promise the world in the lab then fizzle out once people actually take them.

Comments

  • fasted_scientist: Ngl I’ve tinkered with a senolytic combo (dasatinib plus quercetin) for a few months just to see how I felt. Subjectively I didn’t notice any big shift in energy or recovery – could just be placebo or my baseline noise. The preclinical 70% figure is eye‑catching, but until we see solid human trials showing cleared senescent cells and measurable health outcomes I stay skeptical. It’s worth asking what biomarkers they’re using in those studies and whether any early human data exist yet. What’s yo
  • optimizer_jenna: Tbh I haven’t tried any senolytics yet but I’m also wondering which markers they use to count cleared cells in humans and if any early trials show changes in things like inflammation or vascular function.
  • restlessemma: I haven’t tried dasatinib‑quercetin myself yet, but I’m watching the human trials closely. The jump from clearing cells in a dish to feeling better is huge, and biomarkers like p16 or SASP in blood would help bridge that gap. Curious what you’d look for first.
  • student748: Thanks restlessemma, about the biomarker gap. For me I’d start with circulating p16INK4a and SASP markers like IL‑6 before trying anything, plus track fasting glucose and recovery times from my long runs to see if anything shifts.
  • student748: Yeah nah I haven’t tried any senolytics either but I dug into a couple of early human trials – they used SA‑β‑gal staining in skin biopsies and plasma IL‑6 CRP as inflammation markers, plus flow‑mediated dilation for vascular function. Did you see which markers they highlighted?
  • fasted_scientist: Ngl I saw they mentioned SA‑β‑gal staining in skin biopsies, plasma IL‑6 and CRP, plus flow‑mediated dilation for vascular function. Did they flag any of those as the main outcome, or were they all secondary?
  • student748: Yeah nah i feel the same – the 70% number grabs attention but until we see human data clearing senescent cells and improving real outcomes i’m staying cautious. I haven’t tried a senolytic stack yet, mostly watching biomarkers like p16 and sasP in early trials. What markers did they use in that dasatinib‑quercetin run you did?

Community discussion - research and educational context only. Not medical advice.